Impairment of GH responsiveness to combined GH-releasing hormone and arginine administration in adult patients with Prader-Willi syndrome
- PMID: 16984242
- DOI: 10.1111/j.1365-2265.2006.02621.x
Impairment of GH responsiveness to combined GH-releasing hormone and arginine administration in adult patients with Prader-Willi syndrome
Abstract
Objective: It is unclear if poor health outcomes of adult patients with Prader-Willi syndrome (PWS) are influenced by GH deficiency (GHD). Few studies have been focused on PWS adults, but further information on the concomitant role of obesity on GH/IGF-I axis function is needed. The aim of our study was to investigate the prevalence of GHD in a large group of adult subjects with genetically confirmed PWS.
Design and subjects: We studied the GH response to a combined administration of GHRH (1 microg/kg i.v. at 0 minutes) and arginine (ARG) (30 g i.v., infused from 0 to 30 minutes) as well as the baseline IGF-I levels, in a group of 44 PWS adults (18 males, 26 females) aged 18-41.1 years. The same protocol was carried out in a control group of 17 obese subjects (7 males, 10 females) aged 21.8-45.8 years.
Measurements: Blood samples were taken at -15 and 0 minutes and then 30, 45, 60, 90 and 120 minutes after GHRH administration. Serum GH and total IGF-I concentrations were measured by chemioluminescence. Statistical analysis was performed by Student's t-test for unpaired data, and using analysis of variance for parametric and nonparametric (Mann-Whitney test) data, where appropriate. The relationship between pairs of variables was assessed by Pearson's correlation. Independent variables influencing GH secretion were tested by multiple linear regression analysis.
Results: The GH response to GHRH + ARG was significantly lower in PWS patients (GH peak (mean +/- SE) 8.4 +/- 1.2 microg/l; AUC: 471.4 +/- 77.8 microg/l/h) than obese subjects (GH peak 15.7 +/- 2.9 microg/l, P < 0.02; AUC 956 +/- 182.9 microg/l/h, P < 0.005). When considered individually, 17 of 44 PWS individuals (38.6%) were severely GHD, according to the cut-off limit of 4.1 microg/l for obese individuals, and low IGF-I-values were present in 33 PWS patients. Moreover, impaired GH response was combined with subnormal IGF-I levels in all PWS patients with GHD.
Conclusions: Adult subjects with PWS had a reduced responsiveness to GHRH + ARG administration associated with reduced IGF-I levels. In addition, a severe GHD for age was demonstrated in a significant percentage of PWS subjects. These findings are in agreement with the hypothesis that a complex derangement of hypothalamus-pituitary axis occurred in PWS, and suggested that impaired GH secretion is not an artefact of obesity.
Similar articles
-
GH response to GHRH combined with pyridostigmine or arginine in different conditions of low somatotrope secretion in adulthood: obesity and Cushing's syndrome in comparison with hypopituitarism.Panminerva Med. 1998 Mar;40(1):13-7. Panminerva Med. 1998. PMID: 9573747
-
Growth hormone deficiency (GHD) in adult thalassaemic patients.Clin Endocrinol (Oxf). 2007 Nov;67(5):790-5. doi: 10.1111/j.1365-2265.2007.02965.x. Epub 2007 Jul 3. Clin Endocrinol (Oxf). 2007. PMID: 17608814
-
GH response to GHRH combined with pyridostigmine or arginine in different conditions of low somatotrope secretion in adulthood: obesity and Cushing's syndrome in comparison with hypopituitarism.Minerva Endocrinol. 1999 Sep-Dec;24(3-4):107-11. Minerva Endocrinol. 1999. PMID: 10953725
-
Diagnosis of adult GH deficiency.Growth Horm IGF Res. 2008 Feb;18(1):1-16. doi: 10.1016/j.ghir.2007.07.004. Epub 2007 Sep 4. Growth Horm IGF Res. 2008. PMID: 17766155 Review.
-
Growth hormone therapy for Prader-Willi syndrome: a critical appraisal.J Pediatr Endocrinol Metab. 2004 Sep;17 Suppl 4:1297-306. J Pediatr Endocrinol Metab. 2004. PMID: 15506076 Review.
Cited by
-
Growth hormone therapy for Prader-willi syndrome: challenges and solutions.Ther Clin Risk Manag. 2016 Jun 2;12:873-81. doi: 10.2147/TCRM.S70068. eCollection 2016. Ther Clin Risk Manag. 2016. PMID: 27330297 Free PMC article. Review.
-
Growth Hormone Response to L-Arginine Alone and Combined with Different Doses of Growth Hormone-Releasing Hormone: A Systematic Review and Meta-Analysis.Int J Endocrinol. 2022 Nov 23;2022:8739289. doi: 10.1155/2022/8739289. eCollection 2022. Int J Endocrinol. 2022. PMID: 36467462 Free PMC article. Review.
-
Prevalence of growth hormone (GH) deficiency in previously GH-treated young adults with Prader-Willi syndrome.Clin Endocrinol (Oxf). 2019 Jul;91(1):118-123. doi: 10.1111/cen.13988. Epub 2019 Apr 30. Clin Endocrinol (Oxf). 2019. PMID: 30973645 Free PMC article.
-
Growth hormone secretion among adult patients with Prader-Willi syndrome due to different genetic subtypes.J Endocrinol Invest. 2011 Jul-Aug;34(7):493-7. doi: 10.3275/7203. Epub 2010 Jul 22. J Endocrinol Invest. 2011. PMID: 20651469
-
Growth hormone treatment in adults with Prader-Willi syndrome: the Scandinavian study.Endocrine. 2012 Apr;41(2):191-9. doi: 10.1007/s12020-011-9560-4. Epub 2011 Nov 12. Endocrine. 2012. PMID: 22081257 Review.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical